Immune profiling of patients with R/R NKTCL demonstrated maintenance of CD38– naïve B cells and depletion of plasmablasts and plasma cell B subtypes following daratumumab treatment. This evidence concerns the gene CD38 and extranodal nasal NK/T cell lymphoma.